MI‑773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1
- Authors:
- Yan-Ling Chen
- Zi-Mu Zhang
- Xiao-Lu Li
- Yan-Fang Tao
- Shui-Yan Wu
- Fang Fang
- Yi Xie
- Xin-Mei Liao
- Gen Li
- Di Wu
- Hai-Rong Wang
- Ran Zuo
- Hai-Bo Cao
- Jing-Jing Pan
- Juan-Juan Yu
- Zheng Zhang
- Xin-Ran Chu
- Yong-Ping Zhang
- Chen-Xi Feng
- Jian-Wei Wang
- Jun Lu
- Shao-Yan Hu
- Zhi-Heng Li
- Jian Pan
-
Affiliations: School of Basic Medicine and Biological Sciences, Soochow University, Suzhou, Jiangsu 215003, P.R. China, Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, Jiangsu 215003, P.R. China, Intensive Care Unit, Children's Hospital of Soochow University, Suzhou, Jiangsu 215003, P.R. China, Department of Hematology, Children's Hospital of Soochow University, Suzhou, Jiangsu 215003, P.R. China - Published online on: October 18, 2021 https://doi.org/10.3892/ol.2021.13099
- Article Number: 838
This article is mentioned in:
Abstract
Conter HJ, Gopalakrishnan V, Ravi V, Ater JL, Patel S and Araujo DM: Adult versus pediatric neuroblastoma: The M.D. Anderson Cancer Center experience. Sarcoma. 2014:3751512014. View Article : Google Scholar : PubMed/NCBI |
|
Barbieri E, De Preter K, Capasso M, Johansson P, Man TK, Chen Z, Stowers P, Tonini GP, Speleman F and Shohet JM: A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma. PLoS One. 8:e798432013. View Article : Google Scholar : PubMed/NCBI |
|
Lerone M, Ognibene M, Pezzolo A, Martucciello G, Zara F, Morini M and Mazzocco K: Molecular genetics in neuroblastoma prognosis. Children (Basel). 8:4562021.PubMed/NCBI |
|
Smith V and Foster J: High-risk neuroblastoma treatment review. Children (Basel). 5:1142018.PubMed/NCBI |
|
Donghi R, Longoni A, Pilotti S, Michieli P, Porta GD and Pierotti MA: Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest. 91:1753–1760. 1993. View Article : Google Scholar : PubMed/NCBI |
|
Ago K, Shibutani M, Saegusa Y, Shima T, Taniai E and Mitsumori K: A case report of a cerebellar neuroblastoma in a p53 null mutation mouse. J Vet Med Sci. 71:345–347. 2009. View Article : Google Scholar : PubMed/NCBI |
|
Bu X, Shen Z and Jin B: Expression of p53 in nephroblastoma and neuroblastoma. Zhonghua Wai Ke Za Zhi. 35:220–222. 1997.(In Chinese). PubMed/NCBI |
|
Feng Z, Zhang H, Levine AJ and Jin S: The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA. 102:8204–8209. 2005. View Article : Google Scholar : PubMed/NCBI |
|
Yu X, Harris SL and Levine AJ: The regulation of exosome secretion: A novel function of the p53 protein. Cancer Res. 66:4795–4801. 2006. View Article : Google Scholar : PubMed/NCBI |
|
Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, de Graaf P, Francoz S, Gasparini P, Gobbi A, et al: Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol. 24:5835–5843. 2004. View Article : Google Scholar : PubMed/NCBI |
|
Oliner JD, Saiki AY and Caenepeel S: The role of MDM2 amplification and overexpression in tumorigenesis. Cold Spring Harb Perspect Med. 6:a0263362016. View Article : Google Scholar : PubMed/NCBI |
|
Gamble LD, Kees UR, Tweddle DA and Lunec J: MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene. 31:752–763. 2012. View Article : Google Scholar : PubMed/NCBI |
|
Nicolai S, Pieraccioli M, Peschiaroli A, Melino G and Raschella G: Neuroblastoma: Oncogenic mechanisms and therapeutic exploitation of necroptosis. Cell Death Dis. 6:e20102015. View Article : Google Scholar : PubMed/NCBI |
|
Isaacs JS, Saito S and Neckers LM: Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma. J Biol Chem. 276:18497–18506. 2001. View Article : Google Scholar : PubMed/NCBI |
|
Inomistova MV, Svergun NM, Khranovska NM, Skachkova OV, Gorbach OI and Klymnyuk GI: Prognostic significance of MDM2 gene expression in childhood neuroblastoma. Exp Oncol. 37:111–115. 2015. View Article : Google Scholar : PubMed/NCBI |
|
Fan YH, Cheng J, Vasudevan SA, Dou J, Zhang H, Patel RH, Ma IT, Rojas Y, Zhao Y, Yu Y, et al: USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis. 4:e8672013. View Article : Google Scholar : PubMed/NCBI |
|
Cheng J, Fan YH, Xu X, Zhang H, Dou J, Tang Y, Zhong X, Rojas Y, Yu Y, Zhao Y, et al: A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis. 5:e10792014. View Article : Google Scholar : PubMed/NCBI |
|
Vogan K, Bernstein M, Leclerc JM, Brisson L, Brossard J, Brodeur GM, Pelletier J and Gros P: Absence of p53 gene mutations in primary neuroblastomas. Cancer Res. 53:5269–5273. 1993.PubMed/NCBI |
|
Diskin SJ, Capasso M, Diamond M, Oldridge DA, Conkrite K, Bosse KR, Russell MR, Iolascon A, Hakonarson H, Devoto M and Maris JM: Rare variants in TP53 and susceptibility to neuroblastoma. J Natl Cancer Inst. 106:dju0472014. View Article : Google Scholar : PubMed/NCBI |
|
Imamura J, Bartram CR, Berthold F, Harms D, Nakamura H and Koeffler HP: Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res. 53:4053–4058. 1993.PubMed/NCBI |
|
Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, et al: Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA. 105:3933–3938. 2008. View Article : Google Scholar : PubMed/NCBI |
|
Canner JA, Sobo M, Ball S, Hutzen B, DeAngelis S, Willis W, Studebaker AW, Ding K, Wang S, Yang D and Lin J: MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br J Cancer. 101:774–781. 2009. View Article : Google Scholar : PubMed/NCBI |
|
Wang S, Sun W, Zhao Y, McEachern D, Meaux I, Barrière C, Stuckey JA, Meagher JL, Bai L, Liu L, et al: SAR405838: An optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 74:5855–5865. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Bill KL, Garnett J, Meaux I, Ma X, Creighton CJ, Bolshakov S, Barriere C, Debussche L, Lazar AJ, Prudner BC, et al: SAR405838: A novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma. Clin Cancer Res. 22:1150–1160. 2016. View Article : Google Scholar : PubMed/NCBI |
|
Chessari G, Hardcastle IR, Ahn JS, Anil B, Anscombe E, Bawn RH, Bevan LD, Blackburn TJ, Buck I, Cano C, et al: Structure-based design of potent and orally active isoindolinone inhibitors of MDM2-p53 protein-protein interaction. J Med Chem. 64:4071–4088. 2021. View Article : Google Scholar : PubMed/NCBI |
|
Burmakin M, Shi Y, Hedström E, Kogner P and Selivanova G: Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res. 19:5092–5103. 2013. View Article : Google Scholar : PubMed/NCBI |
|
Tesson M, Vasan R, Hock A, Nixon C, Rae C, Gaze M and Mairs R: An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma. Oncotarget. 9:29082–29096. 2018. View Article : Google Scholar : PubMed/NCBI |
|
Chen L, Rousseau RF, Middleton SA, Nichols GL, Newell DR, Lunec J and Tweddle DA: Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 6:10207–10221. 2015. View Article : Google Scholar : PubMed/NCBI |
|
Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, et al: Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci Transl Med. 10:eaao30032018. View Article : Google Scholar : PubMed/NCBI |
|
Fang DD, Tang Q, Kong Y, Rong T, Wang Q, Li N, Fang X, Gu J, Xiong D, Yin Y, et al: MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models. Cell Death Discov. 7:902021. View Article : Google Scholar : PubMed/NCBI |
|
Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, Shangary S, Gao W, Qin D, Stuckey J, Krajewski K, et al: Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem. 49:3432–3435. 2006. View Article : Google Scholar : PubMed/NCBI |
|
Aziz MH, Shen H and Maki CG: Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene. 30:4678–4686. 2011. View Article : Google Scholar : PubMed/NCBI |
|
Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling A, Rödel F, et al: Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2:e2432011. View Article : Google Scholar : PubMed/NCBI |
|
Lu J, Guan S, Zhao Y, Yu Y, Wang Y, Shi Y, Mao X, Yang KL, Sun W, Xu X, et al: Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma. Oncotarget. 7:82757–82769. 2016. View Article : Google Scholar : PubMed/NCBI |
|
Li Z, Li X, Xu L, Tao Y, Yang C, Chen X, Fang F, Wu Y, Ding X, Zhao H, et al: Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4. Oncol Rep. 38:2705–2716. 2017. View Article : Google Scholar : PubMed/NCBI |
|
Yu G, Wang LG, Han Y and He QY: ClusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI |
|
Li ZH, Du WW, Xu LX, Zhao H, Li XL, Fang F, Wu Y, Lu J, Li YH, Du WW, et al: A novel sphingosine kinase 1 inhibitor (SKI-5C) induces cell death of Wilms' tumor cells in vitro and in vivo. Am J Transl Res. 8:4548–4563. 2016.PubMed/NCBI |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI |
|
Morales La Madrid A, Campbell N, Smith S, Cohn SL and Salgia R: Targeting ALK: A promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 7:199–210. 2012. View Article : Google Scholar : PubMed/NCBI |
|
Lee H, Ren J, Pesavento RP, Ojeda I, Rice AJ, Lv H, Kwon Y and Johnson ME: Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling. Bioorg Med Chem. 27:1981–1989. 2019. View Article : Google Scholar : PubMed/NCBI |
|
Chen C and Lan MS: A promoter-driven assay for INSM1-associated signaling pathway in neuroblastoma. Cell Signal. 76:1097852020. View Article : Google Scholar : PubMed/NCBI |
|
Pieters R, Schrappe M, De Lorenzo P, Hann I, Rossi GD, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, et al: A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomised trial. Lancet. 370:240–250. 2007. View Article : Google Scholar : PubMed/NCBI |
|
Timmerman DM, Remmers TL, Hillenius S and Looijenga LHJ: Mechanisms of TP53 pathway inactivation in embryonic and somatic cells-relevance for understanding (Germ Cell) tumorigenesis. Int J Mol Sci. 22:53772021. View Article : Google Scholar : PubMed/NCBI |
|
Rivlin N, Brosh R, Oren M and Rotter V: Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. Genes Cancer. 2:466–474. 2011. View Article : Google Scholar : PubMed/NCBI |
|
Martin-Caballero J, Flores JM, Garcia-Palencia P and Serrano M: Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res. 61:6234–6238. 2001.PubMed/NCBI |
|
Zhang Y, Xiong Y and Yarbrough GW: ARF Promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:725–734. 1998. View Article : Google Scholar : PubMed/NCBI |
|
Liu J, Zhang C, Wang XL, Ly P, Belyi V, Xu-Monette ZY, Young KH, Hu W and Feng Z: E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell Death Differ. 21:1792–1804. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Moll UM and Petrenko O: The MDM2-p53 interaction. Mol Cancer Res. 1:1001–1008. 2003.PubMed/NCBI |
|
Tweddle DA, Pearson ADJ, Haber M, Norris MD, Xue C, Flemming C and Lunec J: The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 197:93–98. 2003. View Article : Google Scholar : PubMed/NCBI |
|
Goldschneider D, Horvilleur E, Plassa LF, Guillaud-Bataille M, Million K, Wittmer-Dupret E, Danglot G, de Thé H, Bénard J, May E and Douc-Rasy S: Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res. 34:5603–5612. 2006. View Article : Google Scholar : PubMed/NCBI |
|
Wolter J, Angelini P and Irwin M: p53 family: Therapeutic targets in neuroblastoma. Future Oncol. 6:429–444. 2010. View Article : Google Scholar : PubMed/NCBI |
|
Zhao Y, Liu L, Sun W, Lu J, McEachern D, Li X, Yu S, Bernard D, Ochsenbein P, Ferey V, et al: Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. J Am Chem Soc. 135:7223–7234. 2013. View Article : Google Scholar : PubMed/NCBI |
|
Van Maerken T, Vandesompele J, Rihani A, De Paepe A and Speleman F: Escape from p53-mediated tumor surveillance in neuroblastoma: Switching off the p14(ARF)-MDM2-p53 axis. Cell Death Differ. 16:1563–1572. 2009. View Article : Google Scholar : PubMed/NCBI |
|
Nor F, Warner KA, Zhang Z, Acasigua GA, Pearson AT, Kerk SA, Helman JI, Filho MS, Wang S and Nör JE: Therapeutic inhibition of the MDM2-p53 interaction prevents recurrence of adenoid cystic carcinomas. Clin Cancer Res. 23:1036–1048. 2017. View Article : Google Scholar : PubMed/NCBI |
|
Andrews A, Warner K, Rodriguez-Ramirez C, Pearson AT, Nör F, Zhang Z, Kerk S, Kulkarni A, Helman JI, Brenner JC, et al: Ablation of cancer stem cells by therapeutic inhibition of the MDM2-p53 interaction in mucoepidermoid carcinoma. Clin Cancer Res. 25:1588–1600. 2019. View Article : Google Scholar : PubMed/NCBI |
|
de Jonge M, de Weger VA, Dickson MA, Langenberg M, Cesne AL, Wagner AJ, Hsu K, Zheng W, Macé S, Tuffal G, et al: A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. Eur J Cancer. 76:144–151. 2017. View Article : Google Scholar : PubMed/NCBI |
|
Mahalakshmi B, Baskaran R, Shanmugavadivu M, Nguyen NT and Velmurugan BK: Insulinoma-associated protein 1 (INSM1): A potential biomarker and therapeutic target for neuroendocrine tumors. Cell Oncol (Dordr). 43:367–376. 2020. View Article : Google Scholar : PubMed/NCBI |
|
Sanz G, Singh M, Peuget S and Selivanova G: Inhibition of p53 inhibitors: Progress, challenges and perspectives. J Mol Cell Biol. 11:586–599. 2019. View Article : Google Scholar : PubMed/NCBI |
|
Breslin MB, Zhu M, Notkins AL and Lan MS: Neuroendocrine differentiation factor, IA-1, is a transcriptional repressor and contains a specific DNA-binding domain: Identification of consensus IA-1 binding sequence. Nucleic Acids Res. 30:1038–1045. 2002. View Article : Google Scholar : PubMed/NCBI |
|
Chen C, Breslin MB and Lan MS: INSM1 increases N-myc stability and oncogenesis via a positive-feedback loop in neuroblastoma. Oncotarget. 6:36700–36712. 2015. View Article : Google Scholar : PubMed/NCBI |